Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleanor J Cheadle

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Current Opinion in Molecular Therapeutics|March 2, 2006
MT-103 Micromet/MedImmuneEleanor J Cheadle
Immunotherapy|September 4, 2013
Targeting T cells to tumor: exploiting the chimeric antibody receptorDavid E Gilham, Eleanor J Cheadle
Immunology|September 13, 2002
Bugs as drugs for cancerEleanor J Cheadle, Andrew M Jackson
Leukemia & Lymphoma|September 20, 2013
New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumorTim M Illidge, Eleanor J Cheadle, Jamie Honeychurch
Cancers|May 4, 2026
The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal CancerSreya Wadud, Eleanor J Cheadle, Paul A Sutton
Cancers|October 3, 2020
Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy ResponseShuhui Cheng, Eleanor J Cheadle, Timothy M Illidge
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 7, 2005
Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulinAnne C Armstrong, Eleanor J Cheadle, Robert E Hawkins
British Journal of Haematology|May 15, 2008
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphomaEleanor J Cheadle, David E Gilham, Robert E Hawkins
Expert Opinion on Biological Therapy|September 6, 2014
Update on obinutuzumab in the treatment of B-cell malignanciesTim Illidge, Eleanor J Cheadle, Claire Donaghy, et al.
Immunology|January 10, 2003
Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanismEleanor J Cheadle, Peter J Selby, Andrew M Jackson
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Current Opinion in Molecular Therapeutics|March 2, 2006
MT-103 Micromet/MedImmuneEleanor J Cheadle
Immunotherapy|September 4, 2013
Targeting T cells to tumor: exploiting the chimeric antibody receptorDavid E Gilham, Eleanor J Cheadle
Immunology|September 13, 2002
Bugs as drugs for cancerEleanor J Cheadle, Andrew M Jackson
Leukemia & Lymphoma|September 20, 2013
New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumorTim M Illidge, Eleanor J Cheadle, Jamie Honeychurch
Cancers|May 4, 2026
The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal CancerSreya Wadud, Eleanor J Cheadle, Paul A Sutton
Cancers|October 3, 2020
Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy ResponseShuhui Cheng, Eleanor J Cheadle, Timothy M Illidge
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 7, 2005
Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulinAnne C Armstrong, Eleanor J Cheadle, Robert E Hawkins
British Journal of Haematology|May 15, 2008
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphomaEleanor J Cheadle, David E Gilham, Robert E Hawkins
Expert Opinion on Biological Therapy|September 6, 2014
Update on obinutuzumab in the treatment of B-cell malignanciesTim Illidge, Eleanor J Cheadle, Claire Donaghy, et al.
Immunology|January 10, 2003
Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanismEleanor J Cheadle, Peter J Selby, Andrew M Jackson
Pageof 4